- Home
- EYPT vs DNA Comparison
EYPT vs DNA Comparison
Compare EYPT & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYPT
- DNA
- Stock Information
- Founded
- EYPT 1987
- DNA 2008
- Country
- EYPT United States
- DNA United States
- Employees
- EYPT N/A
- DNA N/A
- Industry
- EYPT Biotechnology: Laboratory Analytical Instruments
- DNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EYPT Industrials
- DNA Health Care
- Exchange
- EYPT Nasdaq
- DNA Nasdaq
- Market Cap
- EYPT 427.9M
- DNA 478.8M
- IPO Year
- EYPT 2005
- DNA N/A
- Fundamental
- Price
- EYPT $6.51
- DNA $7.45
- Analyst Decision
- EYPT Strong Buy
- DNA Sell
- Analyst Count
- EYPT 8
- DNA 5
- Target Price
- EYPT $25.71
- DNA $17.25
- AVG Volume (30 Days)
- EYPT 841.5K
- DNA 1.5M
- Earning Date
- EYPT 05-07-2025
- DNA 05-08-2025
- Dividend Yield
- EYPT N/A
- DNA N/A
- EPS Growth
- EYPT N/A
- DNA N/A
- EPS
- EYPT N/A
- DNA N/A
- Revenue
- EYPT $43,273,000.00
- DNA $227,043,000.00
- Revenue This Year
- EYPT N/A
- DNA N/A
- Revenue Next Year
- EYPT N/A
- DNA $16.85
- P/E Ratio
- EYPT N/A
- DNA N/A
- Revenue Growth
- EYPT N/A
- DNA N/A
- 52 Week Low
- EYPT $3.91
- DNA $5.00
- 52 Week High
- EYPT $21.26
- DNA $45.20
- Technical
- Relative Strength Index (RSI)
- EYPT 61.19
- DNA 50.71
- Support Level
- EYPT $5.37
- DNA $7.13
- Resistance Level
- EYPT $5.86
- DNA $8.58
- Average True Range (ATR)
- EYPT 0.57
- DNA 0.80
- MACD
- EYPT 0.20
- DNA 0.24
- Stochastic Oscillator
- EYPT 99.81
- DNA 68.56
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.